Likewise, Hydroxyurea, the only therapeutic alternative commercially available for SCD patients, acts by promoting fetal Hb levels but also by increasing NO production, and has been shown to reduce albuminuria and protect renal function. Here, GSTM1 is linked to Schnyder corneal dystrophy.